Anksilon (Buspirone)
Non-benzodiazepine anxiolytic for the treatment of generalised anxiety disorder
Anksilon contains buspirone hydrochloride, a non-benzodiazepine anxiolytic medication used for the treatment of clinically significant anxiety disorders, including generalised anxiety disorder (GAD). Unlike benzodiazepines, buspirone does not cause significant sedation, physical dependence, or withdrawal symptoms, making it a valuable alternative for patients requiring longer-term anxiety management. The medication works by acting on serotonin receptors in the brain and typically requires 1–2 weeks of regular dosing before therapeutic effects become apparent.
Quick Facts
Key Takeaways
- Anksilon (buspirone) is a non-benzodiazepine anxiolytic that treats generalised anxiety disorder without causing significant sedation or physical dependence.
- Therapeutic effects are not immediate — it typically takes 1–2 weeks of regular use before improvement begins, with full effects developing over 4–6 weeks.
- Buspirone must never be combined with MAO inhibitors, and careful monitoring is needed when used alongside serotonergic medications due to the risk of serotonin syndrome.
- Unlike benzodiazepines, buspirone has no significant abuse potential and is not classified as a controlled substance in most countries.
- The medication is not suitable for children under 18 years, during pregnancy, or while breastfeeding, and should not be used for acute anxiety relief or panic attacks.
What Is Anksilon and What Is It Used For?
Quick Answer: Anksilon contains buspirone hydrochloride and is prescribed for the treatment of symptoms associated with clinically significant anxiety disorders, particularly generalised anxiety disorder (GAD). It relieves anxiety, worry, and tension through a unique mechanism that differs fundamentally from benzodiazepines.
Anksilon belongs to the azapirone class of anxiolytic medications, which represents a distinct pharmacological category from benzodiazepines. First approved by the U.S. Food and Drug Administration (FDA) in 1986, buspirone was developed as an alternative anxiolytic agent that could provide effective anxiety relief without the sedation, cognitive impairment, muscle relaxation, and dependence risk associated with benzodiazepines. The drug has since gained approval in numerous countries worldwide and is included in many national formularies as a recommended treatment option for generalised anxiety disorder.
The primary indication for Anksilon is the management of generalised anxiety disorder (GAD), a condition characterised by persistent, excessive worry and anxiety about a variety of events and activities that is difficult to control. According to the World Health Organization (WHO), anxiety disorders are among the most prevalent mental health conditions globally, affecting an estimated 301 million people worldwide in 2019. GAD specifically has a lifetime prevalence of approximately 5–6% in the general population, with women being affected roughly twice as often as men.
Mechanism of Action
Buspirone’s mechanism of action is fundamentally different from that of benzodiazepines. While benzodiazepines work by enhancing the effect of the inhibitory neurotransmitter GABA at GABA-A receptors, buspirone acts primarily as a partial agonist at serotonin 5-HT1A receptors. These receptors are found in high concentrations in brain regions associated with anxiety, mood regulation, and emotional processing, including the hippocampus, dorsal raphe nucleus, and prefrontal cortex.
As a partial agonist, buspirone activates 5-HT1A receptors to a moderate degree — sufficiently to produce anxiolytic effects, but without the full stimulation that would occur with a complete agonist. At presynaptic 5-HT1A autoreceptors in the dorsal raphe nucleus, buspirone initially reduces serotonin neuron firing. However, with continued treatment over 1–2 weeks, these autoreceptors become desensitised, leading to a gradual restoration and ultimately an increase in serotonergic neurotransmission. This delayed desensitisation process explains why buspirone requires several weeks of regular dosing before its full therapeutic benefits emerge.
Additionally, buspirone has moderate affinity for dopamine D2 receptors, acting as both a partial agonist and antagonist depending on the prevailing dopaminergic tone. Its active metabolite, 1-pyrimidinylpiperazine (1-PP), has alpha-2 adrenergic antagonist activity, which may contribute additional anxiolytic and antidepressant properties. Importantly, buspirone has no significant affinity for GABA-benzodiazepine receptors, which is why it does not produce the sedation, muscle relaxation, anticonvulsant effects, or dependence potential characteristic of benzodiazepines.
Pharmacokinetics
Buspirone is rapidly and almost completely absorbed from the gastrointestinal tract after oral administration. However, it undergoes extensive first-pass metabolism in the liver, resulting in an oral bioavailability of only approximately 4%. Food increases the bioavailability of buspirone by reducing the extent of first-pass metabolism, which is why patients are advised to take their medication consistently either with or without food at the same time each day.
The drug is extensively metabolised in the liver, primarily by the cytochrome P450 enzyme CYP3A4, which makes it susceptible to interactions with CYP3A4 inhibitors and inducers. The major active metabolite, 1-(2-pyrimidinyl)piperazine (1-PP), has approximately one-quarter the anxiolytic activity of the parent compound. The elimination half-life of buspirone is approximately 2–3 hours, necessitating administration two to three times daily to maintain therapeutic plasma levels. Steady-state plasma concentrations are achieved within approximately 2 days of regular dosing.
Clinical Advantages
Buspirone offers several clinically significant advantages over benzodiazepines for the management of anxiety disorders. The American Psychiatric Association (APA) Practice Guidelines for the Treatment of Anxiety Disorders recognise buspirone as an appropriate first-line or adjunctive treatment for GAD. Key advantages include the absence of significant sedation, no impairment of psychomotor performance at therapeutic doses, no potentiation of alcohol effects, no risk of physical dependence or withdrawal syndrome, no abuse potential, and no respiratory depression. These properties make buspirone particularly suitable for patients who need to remain alert and functional during treatment, those with a history of substance abuse, elderly patients at risk of falls, and individuals requiring long-term anxiety management.
What Should You Know Before Taking Anksilon?
Quick Answer: Anksilon must not be used if you are allergic to buspirone, have acute angle-closure glaucoma, myasthenia gravis, severe liver or kidney disease, epilepsy, or acute poisoning from alcohol, sedatives, or psychotropic medications. It must never be combined with MAO inhibitors. Special caution is needed in patients switching from benzodiazepines.
Contraindications
Anksilon must not be used in the following situations:
- Hypersensitivity: Known allergy to buspirone hydrochloride or any of the excipients in the formulation. Signs of an allergic reaction may include itching, difficulty breathing, or swelling of the face, lips, throat, or tongue.
- Acute angle-closure glaucoma: This ophthalmic condition involves dangerously elevated intraocular pressure, and buspirone should be avoided in patients with this condition.
- Myasthenia gravis: This autoimmune neuromuscular disorder causes severe muscle weakness, and buspirone use may potentially worsen symptoms.
- Severe liver or kidney disease: Because buspirone is extensively metabolised by the liver and its metabolites are excreted by the kidneys, severe impairment of either organ can lead to dangerous drug accumulation.
- Epilepsy: Patients with epilepsy or a history of seizure disorders should not use buspirone, as it may lower the seizure threshold.
- Acute intoxication: Buspirone must not be used during acute poisoning with alcohol, sedatives (sleeping pills), analgesics (pain medications), or psychotropic medications.
Anksilon must never be used concurrently with monoamine oxidase inhibitors (MAO inhibitors) such as phenelzine or tranylcypromine, which are used for depression and Parkinson’s disease. The combination can lead to dangerous increases in blood pressure and potentially life-threatening serotonin syndrome. A washout period of at least 14 days is required after discontinuing an MAO inhibitor before starting buspirone.
Warnings and Precautions
Before using Anksilon, discuss the following conditions with your healthcare provider, as dose adjustment or close monitoring may be required:
- Switching from benzodiazepines: If you have been taking a benzodiazepine (such as diazepam, alprazolam, or lorazepam) for a prolonged period, these medications must be tapered gradually before starting buspirone. Buspirone does not prevent benzodiazepine withdrawal symptoms and cannot substitute for benzodiazepines during tapering.
- Mild to moderate kidney or liver disease: Lower doses may be necessary, and your doctor will individually adjust your dosage.
- History of seizures: Although buspirone is contraindicated in epilepsy, patients with a past history of seizures should be carefully evaluated before treatment.
- History of drug dependence: While buspirone has minimal abuse potential compared to benzodiazepines, patients with a history of drug dependence should be monitored appropriately.
Buspirone does not provide immediate relief from anxiety. It typically takes 1–2 weeks before you begin to notice improvement, with full therapeutic effects developing over 4–6 weeks. If your symptoms have not improved after 4–8 weeks of treatment, consult your doctor. Do not increase the dose on your own.
Children and Adolescents
Anksilon must not be used by children and adolescents under 18 years of age. The safety and effectiveness of buspirone have not been established in paediatric patients. Clinical trials in this population have been insufficient to support its use, and regulatory authorities have not approved buspirone for use in individuals under 18.
Pregnancy and Breastfeeding
Pregnancy: Anksilon should not be used during pregnancy. There are insufficient data on the use of buspirone in pregnant women. Animal studies have not demonstrated direct harmful effects on fertility or foetal development at therapeutic doses, but the potential risk to the human foetus is unknown. If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before using this medication. Your doctor will weigh the potential benefits against the risks.
Breastfeeding: Breastfeeding is not recommended during treatment with Anksilon. It is not known whether buspirone or its metabolites pass into human breast milk. Given the potential for adverse effects in the nursing infant, a decision should be made to either discontinue breastfeeding or discontinue the medication, taking into account the importance of the treatment to the mother.
Driving and Operating Machinery
Do not drive or operate machinery until you know how Anksilon affects you. Although buspirone is less sedating than benzodiazepines, it may still impair your reaction time, particularly at the beginning of treatment and after dose changes. You are personally responsible for assessing whether you are fit to drive or perform activities requiring alertness. Discuss with your doctor or pharmacist if you are unsure.
Alcohol and Grapefruit
Alcohol: Do not drink alcohol while taking Anksilon. Although buspirone does not potentiate the sedative effects of alcohol to the same extent as benzodiazepines, the combination may still increase drowsiness and impair judgement and coordination.
Grapefruit juice: Do not consume large quantities of grapefruit or grapefruit juice while taking Anksilon. Grapefruit inhibits the CYP3A4 enzyme that metabolises buspirone, which can significantly increase blood levels of the drug and enhance its effects and side effects.
Excipient Information
Lactose: Each 5 mg tablet contains 59.5 mg of lactose (as monohydrate) and each 10 mg tablet contains 118.9 mg of lactose (as monohydrate). If you have been told by your doctor that you have an intolerance to certain sugars, consult your doctor before taking this medication.
Sodium: This medicine contains less than 1 mmol (23 mg) sodium per tablet, meaning it is essentially sodium-free.
How Does Anksilon Interact with Other Drugs?
Quick Answer: Anksilon has clinically significant interactions with MAO inhibitors (strictly contraindicated), serotonergic medications (risk of serotonin syndrome), CYP3A4 inhibitors (increased buspirone levels), and CYP3A4 inducers (decreased buspirone levels). Always inform your doctor about all medications you are taking.
Buspirone is primarily metabolised by the cytochrome P450 enzyme CYP3A4 in the liver, making it susceptible to pharmacokinetic interactions with drugs that inhibit or induce this enzyme system. Additionally, due to its serotonergic mechanism of action, buspirone can interact pharmacodynamically with other medications that affect serotonin levels, potentially leading to serotonin syndrome — a rare but potentially life-threatening condition characterised by fever, confusion, agitation, sweating, tremors, and rapid heartbeat.
Combining Anksilon with other serotonergic medications can cause serotonin syndrome, a potentially fatal condition. Symptoms include high fever, confusion, agitation, excessive sweating, tremors, muscle twitching, hallucinations, and rapid heartbeat. If you experience any of these symptoms, stop all serotonergic medications and seek emergency medical attention immediately.
Major Interactions
| Drug/Class | Effect of Interaction | Clinical Significance |
|---|---|---|
| MAO inhibitors (phenelzine, tranylcypromine) | Risk of hypertensive crisis and serotonin syndrome | Strictly contraindicated; 14-day washout required |
| SSRIs (fluoxetine, fluvoxamine, paroxetine) | Increased risk of serotonin syndrome; CYP3A4 inhibition may increase buspirone levels | Dose adjustment and close monitoring required |
| Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) | Markedly increased buspirone plasma concentrations | Significant dose reduction required or avoid combination |
| Triptans (sumatriptan, zolmitriptan) | Combined serotonergic activity increases serotonin syndrome risk | Caution; monitor for serotonin syndrome symptoms |
| Tramadol | Additive serotonergic effects; increased seizure risk | Use with caution; monitor closely |
| Linezolid (antibiotic) | MAO-inhibiting properties increase serotonin syndrome risk | Avoid combination when possible |
| L-tryptophan / St. John’s Wort | Additive serotonergic effects | Avoid concurrent use |
Moderate Interactions
| Drug/Class | Effect of Interaction | Clinical Significance |
|---|---|---|
| Erythromycin | CYP3A4 inhibition increases buspirone levels | Dose adjustment may be needed |
| Diltiazem / Verapamil | CYP3A4 inhibition; increased buspirone exposure | Monitor for increased side effects |
| Cimetidine | Inhibits buspirone metabolism | Monitor for excessive sedation |
| Nefazodone | Potent CYP3A4 inhibition; additive serotonergic effects | Dose reduction required |
| Haloperidol | Increased haloperidol serum levels | Monitor for haloperidol toxicity |
| Diazepam | Buspirone may increase diazepam levels; additive CNS effects | Monitor for excessive sedation |
| Warfarin | May affect anticoagulant activity | Monitor INR closely |
| Oral contraceptives | May interact with hormonal metabolism | Inform your doctor if taking hormonal contraception |
Enzyme Inducers (Reduced Buspirone Effect)
- Rifampicin (antibiotic): A potent CYP3A4 inducer that can dramatically reduce buspirone plasma levels, potentially rendering it therapeutically ineffective. Concurrent use should be avoided.
- Phenytoin, phenobarbital, carbamazepine (antiepileptics): These enzyme inducers can significantly decrease buspirone blood levels, necessitating dose adjustment or alternative therapy.
- Dexamethasone (corticosteroid): May reduce buspirone efficacy through CYP3A4 induction.
Grapefruit juice is a potent inhibitor of CYP3A4 and can significantly increase buspirone blood levels. In clinical studies, co-administration with grapefruit juice increased buspirone plasma concentrations by several-fold. Avoid consuming large quantities of grapefruit or grapefruit juice during treatment.
What Is the Correct Dosage of Anksilon?
Quick Answer: The recommended starting dose is 5 mg three times daily (15 mg/day). Your doctor may gradually increase the dose to 20–30 mg/day, divided into multiple doses. The maximum single dose is 30 mg, and the maximum daily dose is 60 mg. Always take the tablets at the same time each day.
Always use Anksilon exactly as your doctor has prescribed. Do not change the dose without medical advice. The correct dosage depends on the severity of your condition and your individual response to the medication. Because buspirone has a delayed onset of action, patience is required — do not increase your dose because you have not noticed immediate effects.
Adults (Over 18 Years)
Adult Dosage
Starting dose: 5 mg three times daily (15 mg total daily dose).
Dose adjustment: Your doctor may gradually increase the dose if needed. The daily dose can be increased to 20–30 mg of buspirone hydrochloride, divided across multiple doses throughout the day.
Maximum single dose: 30 mg buspirone hydrochloride.
Maximum daily dose: 60 mg buspirone hydrochloride.
Administration: Tablets should be swallowed whole with an appropriate amount of liquid. Do not crush or chew the tablets. The tablets have a score line and can be divided into two equal halves.
Patients with Kidney or Liver Problems
Dose Adjustments for Organ Impairment
Mild to moderate hepatic impairment: Lower starting doses may be necessary. Your doctor will individually adjust your dosage and monitor you closely.
Mild to moderate renal impairment: Dose reduction may be required. Your doctor will assess kidney function and adjust the dose accordingly.
Severe hepatic or renal impairment: Anksilon is contraindicated. Do not use.
Children and Adolescents
Paediatric Use
Anksilon must not be used by children and adolescents under 18 years of age. Safety and efficacy have not been established in this age group.
How to Take Anksilon
For optimal and consistent therapeutic effect, follow these important instructions:
- Consistency with food: Always take your tablets either on an empty stomach or always after a meal. Food significantly affects the absorption of buspirone, so inconsistent food intake can lead to unpredictable blood levels.
- Same time each day: Take your doses at the same times each day to maintain consistent blood levels.
- Swallow whole: Tablets should be swallowed whole or halved (using the score line) with adequate liquid. Do not crush or chew.
- Duration of treatment: It may take some time before you begin to feel better. If symptoms have not improved within 4–8 weeks, consult your doctor. The doctor will determine how long you should continue taking Anksilon. If long-term treatment is needed, your doctor will review the necessity of continued treatment at regular intervals.
Missed Dose
If you forget a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten one.
Overdose
If you take too much Anksilon, or if a child accidentally ingests the medication, contact your local poison control centre or emergency services immediately. Take the medication packaging with you.
Symptoms of overdose may include:
- Nausea and vomiting
- Dizziness and drowsiness
- Constricted pupils (miosis)
- Abdominal pain
Overdose with buspirone alone is generally less dangerous than overdose with benzodiazepines. However, combined overdose with other CNS-active substances may produce more severe symptoms requiring intensive supportive care.
Stopping Treatment
Continue taking Anksilon until your doctor advises you to stop. Although buspirone has a lower risk of withdrawal than benzodiazepines, this type of medication should not be stopped abruptly. Follow your doctor’s instructions carefully for gradually reducing and discontinuing the medication. If you require long-term treatment, your doctor will regularly review your progress and the ongoing need for continued therapy.
What Are the Side Effects of Anksilon?
Quick Answer: Common side effects include dizziness, headache, nausea, nervousness, drowsiness, insomnia, and dry mouth. Most side effects are mild and transient. Serious but rare effects include serotonin syndrome and allergic reactions, which require immediate medical attention.
Like all medicines, Anksilon can cause side effects, although not everyone will experience them. Most side effects of buspirone are dose-related and tend to diminish as your body adjusts to the medication. Because buspirone does not act on the GABA-benzodiazepine receptor system, it generally causes fewer and less severe side effects than benzodiazepines, particularly regarding sedation, cognitive impairment, and psychomotor slowing.
You experience signs of serotonin syndrome (fever, confusion, agitation, excessive sweating, tremors, hallucinations, rapid heartbeat) or signs of a severe allergic reaction (itching, difficulty breathing, swelling of the face, lips, throat, or tongue). These are rare but potentially life-threatening emergencies.
Common
May affect up to 1 in 10 people
- Nonspecific chest pain
- Nightmares, drowsiness, insomnia, dizziness
- Nervousness, lightheadedness, reduced concentration
- Restlessness, anger, hostility, confusion, depression
- Blurred vision
- Tinnitus (ringing in the ears)
- Sore throat, nasal congestion
- Nausea, dry mouth, gastrointestinal symptoms, diarrhoea
- Headache, weakness
Uncommon
May affect up to 1 in 100 people
- Brief fainting episodes, low or high blood pressure, rapid heart rate or rhythm disturbances
- Depersonalisation, hyperacusis (sensitivity to sounds), euphoria, dysphoria, compulsive movements
- Anxiety, apathy, hallucinations, suicidal thoughts, seizures
- Numbness, tingling sensations (paraesthesia), coordination problems, involuntary tremors
- Increased respiratory rate, shortness of breath, chest tightness, altered sense of smell
- Red eyes, eye itching, conjunctivitis
- Increased or decreased appetite, drooling, rectal bleeding, constipation, flatulence
- Irritable bowel symptoms, vomiting
- Urinary tract symptoms
- Swelling, urticaria (hives), hot flushes, easy bruising, hair loss, dry skin, eczema, blisters
- Muscle cramps, muscle pain, muscle stiffness, joint pain
- Weight gain or loss, fever, head buzzing, fatigue, altered taste, sweating
- Elevated liver enzymes
- Menstrual disturbances, changes in sexual desire
Rare
May affect up to 1 in 1,000 people
- Serotonin syndrome (fever, confusion, agitation, sweating, tremors, hallucinations, muscle twitching, rapid heartbeat)
- Allergic reaction (itching, breathing difficulties, swelling of face, lips, throat, or tongue)
- Cerebrovascular disturbance, heart failure, heart attack, cardiomyopathy, bradycardia
- Blood changes (eosinophilia, leukopenia, thrombocytopenia)
- Mood swings, claustrophobia, cold intolerance, stupor, slurred speech, psychosis, transient amnesia
- Extrapyramidal symptoms (involuntary movements, rigidity, parkinsonism, akathisia, restless legs syndrome)
- Eye pain, photosensitivity, pressure sensation in eyes, tunnel vision
- Nosebleeds
- Urinary incontinence, nocturia
- Small skin haemorrhages, acne, thin nails, muscle weakness
- Galactorrhoea (breast milk production), gynaecomastia (male breast enlargement), thyroid dysfunction
- Alcohol abuse, bleeding disorders, voice loss, hiccups, burning tongue
- Absence of menstruation, pelvic inflammatory disease, ejaculatory dysfunction, impotence
Reporting Side Effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed above. You can also report side effects directly to your national medicines regulatory authority. By reporting side effects, you help provide more information on the safety of this medicine.
How Should You Store Anksilon?
Quick Answer: Store Anksilon out of the sight and reach of children. No special temperature requirements apply. Keep blister packs in the outer carton to protect from light. If using the HDPE tablet bottle, use within 1 year of first opening. Do not use after the expiry date.
Proper storage of medications is essential to maintain their safety and effectiveness. Follow these guidelines to ensure your Anksilon tablets remain in good condition throughout their shelf life:
- Keep out of reach: Store this medicine out of the sight and reach of children at all times.
- Expiry date: Do not use this medicine after the expiry date shown on the carton, bottle, or blister pack. The expiry date refers to the last day of the stated month.
- Temperature: No special storage temperature conditions are required.
- Blister packs: Store the blister pack in the outer carton to protect from light.
- HDPE tablet bottle: Use within 1 year after first opening.
- Disposal: Do not dispose of medicines via household waste or wastewater. Return unused medicines to your pharmacist for proper disposal. These measures help protect the environment.
What Does Anksilon Contain?
Quick Answer: The active substance is buspirone hydrochloride, available in 5 mg and 10 mg tablets. Other ingredients include lactose monohydrate, colloidal anhydrous silica, microcrystalline cellulose, sodium starch glycolate (type A), and magnesium stearate.
Active Substance
- 5 mg tablet: Each tablet contains 5 mg of buspirone hydrochloride.
- 10 mg tablet: Each tablet contains 10 mg of buspirone hydrochloride.
Other Ingredients (Excipients)
The inactive ingredients in Anksilon tablets include:
- Lactose monohydrate
- Colloidal anhydrous silica
- Microcrystalline cellulose
- Sodium starch glycolate (type A)
- Magnesium stearate
Tablet Appearance
5 mg tablets: White or nearly white, oval tablets marked “ORN 30” on one side with a score line on the other side. The tablet can be divided into two equal parts.
10 mg tablets: White or nearly white, oval tablets marked “ORN 31” on one side with a score line on the other side. The tablet can be divided into two equal parts.
Pack Sizes
Blister packs: 20, 30, 50, 60, 90, and 100 tablets.
Bottle: 250 tablets (HDPE container).
Not all pack sizes may be marketed in all countries.
Marketing Authorisation Holder
Orion Corporation, Orionintie 1, FI-02200 Espoo, Finland.
Frequently Asked Questions About Anksilon
Anksilon (buspirone) and benzodiazepines (such as diazepam, alprazolam, and lorazepam) both treat anxiety, but they work through entirely different mechanisms. Benzodiazepines enhance the activity of the neurotransmitter GABA, producing rapid sedation, muscle relaxation, and anxiety relief within minutes to hours. Buspirone, by contrast, acts on serotonin 5-HT1A receptors and takes 1–2 weeks to begin working. The key advantages of buspirone over benzodiazepines include no significant sedation, no physical dependence, no withdrawal syndrome, no abuse potential, and no impairment of psychomotor performance. However, buspirone is not effective for acute anxiety episodes or panic attacks, unlike benzodiazepines.
Yes, buspirone can generally be used for longer periods than benzodiazepines because it does not cause physical dependence or tolerance. However, if long-term treatment is needed, your doctor should regularly review the ongoing necessity of the medication and monitor your progress. The treatment duration is determined individually based on your clinical response and the severity of your anxiety disorder. Always follow your doctor’s recommendations regarding treatment length.
Unlike benzodiazepines, which provide rapid relief, buspirone requires regular daily use for 1–2 weeks before its anxiolytic effects begin to develop. This delay is due to the drug’s mechanism of action: it works by gradually desensitising serotonin autoreceptors in the brain, a process that takes time. Full therapeutic benefit typically develops over 4–6 weeks. It is important not to increase the dose on your own or discontinue treatment prematurely. If you see no improvement after 4–8 weeks, consult your doctor.
No, you cannot simply switch from a benzodiazepine to buspirone. If you have been taking a benzodiazepine for a prolonged period, your body has likely developed physical dependence on it. Buspirone does not act on the same receptors and cannot prevent benzodiazepine withdrawal symptoms. Your doctor must gradually taper and discontinue the benzodiazepine before starting buspirone treatment. Abrupt discontinuation of benzodiazepines can cause serious withdrawal symptoms including seizures.
Buspirone is generally considered a favourable option for elderly patients with anxiety, precisely because it avoids many of the risks associated with benzodiazepines in this population, such as excessive sedation, falls, cognitive impairment, and paradoxical reactions. However, elderly patients may have reduced liver and kidney function, which can affect drug metabolism and clearance. Your doctor may prescribe a lower starting dose and monitor your response carefully. Always inform your doctor about all other medications you are taking, as the risk of drug interactions increases with polypharmacy, which is common in older adults.
Weight changes with buspirone are uncommon. Both weight gain and weight loss have been reported as uncommon side effects, affecting up to 1 in 100 patients. The weight effects of buspirone are generally less pronounced than those associated with some other psychotropic medications. If you notice significant weight changes during treatment, discuss them with your doctor.
References
This article is based on the following peer-reviewed sources and international medical guidelines:
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List, 2023. Geneva: WHO; 2023.
- European Medicines Agency (EMA). Summary of Product Characteristics: Buspirone hydrochloride. Amsterdam: EMA; 2024.
- U.S. Food and Drug Administration (FDA). BuSpar (buspirone hydrochloride) Label. Silver Spring, MD: FDA; Updated 2023.
- British National Formulary (BNF). Buspirone hydrochloride: Indications, dose, interactions, side effects. London: NICE; 2025.
- American Psychiatric Association. Practice Guidelines for the Treatment of Patients with Anxiety Disorders. Arlington, VA: APA; 2023.
- Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017;19(2):93–107. doi:10.31887/DCNS.2017.19.2/bbandelow
- Chessick CA, Allen MH, Thase ME, et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev. 2006;(3):CD006115. doi:10.1002/14651858.CD006115
- Loane C, Politis M. Buspirone: what is it all about? Brain Res. 2012;1461:111–118. doi:10.1016/j.brainres.2012.04.032
- Wilson TK, Tripp J. Buspirone. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2025.
- National Institute for Health and Care Excellence (NICE). Generalised anxiety disorder and panic disorder in adults: management. Clinical guideline [CG113]. London: NICE; Updated 2024.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, consisting of licensed specialist physicians with expertise in clinical pharmacology, psychiatry, and general practice.
All medical content is reviewed by board-certified physicians according to international guidelines from the WHO, EMA, FDA, BNF, and APA. Our editorial process follows the GRADE evidence framework to ensure the highest quality of medical information.
This article is based on Evidence Level 1A: systematic reviews, meta-analyses, and randomised controlled trials from peer-reviewed medical journals and authoritative clinical guidelines. No commercial funding or pharmaceutical industry sponsorship influences our content.